American Journal of Epidemiology Advance Access originally published online on September 12, 2006
American Journal of Epidemiology 2006 164(11):1094-1102; doi:10.1093/aje/kwj320
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL CONTRIBUTIONS |
The Metabolic Syndrome Is Associated with Reduced Risk of Prostate Cancer
1 Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN
2 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Correspondence to Dr. Aaron R. Folsom, Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 1300 South 2nd Street, Suite 300, Minneapolis, MN 55454 (e-mail: folsom{at}epi.umn.edu).
Diabetes is associated with reduced risk of prostate cancer, but whether the metabolic syndrome is associated with prostate cancer is not established. The authors assessed this association in the Atherosclerosis Risk in Communities (ARIC) Study, comprising 6,429 men in four US communities initially with no history of cancer and aged 45–64 years. Metabolic syndrome and other risk factors were assessed in 1987–1989. Follow-up for prostate cancer incidence (n = 385 through 2000) was accomplished through cancer registry and hospital linkage. At baseline, 1,871 men (29.5%) had the metabolic syndrome. After the authors adjusted for other risk factors, men with the metabolic syndrome (
3 components) were significantly less likely to develop prostate cancer (relative risk = 0.77, 95% confidence interval: 0.60, 0.98) than men without the metabolic syndrome. Diabetes was negatively associated with prostate cancer, although the confidence interval included 1 (relative risk = 0.73, 95% confidence interval: 0.51, 1.05). When diabetic participants were excluded, the inverse association between metabolic syndrome and prostate cancer incidence was slightly strengthened. In this study, the metabolic syndrome was associated with decreased prostate cancer incidence. The authors hypothesize that this finding reflects a decrease in bioavailable (free and albumin-bound) testosterone with the metabolic syndrome and a concomitant reduction in prostate cancer risk.
diabetes mellitus; metabolic syndrome X; prospective studies; prostatic neoplasms
Abbreviations: ARIC, Atherosclerosis Risk in Communities
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. R. Folsom, J. S. Pankow, J. M. Peacock, S. J. Bielinski, G. Heiss, and E. Boerwinkle Variation in TCF7L2 and Increased Risk of Colon Cancer: The Atherosclerosis Risk in Communities (ARIC) Study Diabetes Care, May 1, 2008; 31(5): 905 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Folsom, J. M. Peacock, and E. Boerwinkle Sequence Variation in Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease Gene, Low LDL Cholesterol, and Cancer Incidence Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2455 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Borugian, J. J. Spinelli, Z. Sun, L. N. Kolonel, I. Oakley-Girvan, M. D. Pollak, A. S. Whittemore, A. H. Wu, and R. P. Gallagher Prediagnostic C-Peptide and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2164 - 2165. [Full Text] [PDF]
|
|
|
|
 |
|
 A. W Hsing, L. C Sakoda, and S. C Chua Jr Obesity, metabolic syndrome, and prostate cancer Am. J. Clinical Nutrition, September 1, 2007; 86(3): 843S - 857S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Freedland and E. A. Platz Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data Epidemiol. Rev., May 3, 2007; (2007) mxm006v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tuohimaa, L. Tenkanen, H. Syvala, S. Lumme, T. Hakulinen, J. Dillner, and M. Hakama Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 302 - 307. [Abstract] [Full Text] [PDF]
|
|